2022 MDA Clinical and Scientific Conference DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOCTM) for the Treatment of FSHD A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1): MARINA Study Design Understanding the patients’ journey pre- and post-diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis Prevalence of healthcare conditions and services used by patients with myotonic dystrophy pre-and post-diagnosis, a real-world data analysis
